From molecular design to biological response.

Drug discovery, delivery and therapeutic function.

The scientific problem is to connect a therapeutic intervention's design with what reaches the intended cells and what those cells actually do in response. My background in chemical and polymer systems, pulmonary epithelial injury and inhalable drug carriers gives me a credible experimental starting point. I want to extend that foundation to more selective therapies and more decisive measures of biological function, without assuming that one project must address every stage.

How I would approach a PhD laboratory: I would begin with the lab's central biological or chemical problem, then identify one experimentally tractable uncertainty: target dependence, effective tissue exposure, intracellular release or a measured therapeutic response. A medicinal-chemistry project could concentrate on target engagement; a formulation project on transport and release; a pharmacology project on the function of a perturbed pathway. The methods would follow the hypothesis. My longer-term interests include chemical synthesis and bioconjugation, controlled-release materials, nanocarrier formulation, cell-surface engineering, microphysiological systems, imaging, molecular assays and quantitative PK/PD. Computation and AI are optional tools, not defining requirements or claims of mastery.

An experimental precedent: cell-attached polymeric “backpacks” have been used to modulate immune-cell behaviour through sustained local cues, including cytokine-loaded macrophage systems and myeloid-cell approaches in preclinical disease models. This connects materials design, therapeutic delivery, immunopharmacology and manipulation of cellular states. Shields et al., Science Advances (2020) ↗ · Kapate et al., PNAS (2023) ↗.

Explore experimental directions ↗ · See my documented research contributions ↗

Three questions that connect my work.

These are connected scientific questions, not three mandatory stages of every project. Each begins in research I have actually contributed to and leads to techniques I want to understand more deeply.

The experimental reason these questions belong together: A chemical sensor needs evidence of selectivity, not merely a changed optical signal. Plasma-treated PLA needs separate evidence of surface modification and functional performance. An epithelial live/dead assay can quantify injury without establishing a unique protective molecular mechanism. In my ongoing vesicle work, particle stability and aerosol performance address different questions. These studies involve different methods and systems, but all ask whether a measurement supports the conclusion attached to it.

My strongest longer-term interest sits at the interface of these questions, especially in molecular pharmaceutics and chemical biology. But no doctoral laboratory needs to work on all three. Molecular synthesis, polymer-interface physics, biological signalling or quantitative measurement may each be a valid central research problem. The record below distinguishes experimental contributions from future ambitions.

These are legitimate alternative scientific directions, not a requirement that one laboratory cover all six. I would consider research programmes in chemistry, molecular science, pharmaceutical sciences, bioengineering or biomedical science, including fundamental work with no immediate clinical endpoint. The disease area, modality and methods should emerge from the laboratory's question and available expertise. NIH: interdisciplinary biomedical engineering ↗

Three experiments behind the questions.

The following examples show the difference between a result reported by a research team and the part I personally contributed. Original papers and detailed methods remain one click away.

A separate equal-contribution fetal echocardiography machine-learning paper ↗ illustrates another part of my quantitative research, while the complete contribution record retains the distinctions across my other publications. Source figures and publisher pages are linked directly; they are not reproduced here without a figure-specific provenance and reuse check.

Additional publication contributions.

Detailed roles from further publications, including computational work, experimental-only contributions and grant-linked research, remain available below.

What I am working on now.

My MSc research at Qatar University concerns dexamethasone-loaded niosomes and proniosomes intended for pulmonary delivery. The investigation involves formulation design, physicochemical characterization, nebulization and aerosol-performance questions. A stable carrier in a vial is not necessarily a useful carrier after administration; aerosol behavior, tissue exposure and biological activity must be established separately.

This project is ongoing. I do not present proposed or incomplete outcomes as demonstrated efficacy. My academic history also includes imine chemical sensing, polymeric and electrospun materials, cell-based mechanobiology, imaging and quantitative scientific workflows.

Research investigations ↗ · Figures and evidence ↗ · Experimental methods ↗

Molecular therapeutics: questions that interest me.

These examples test the same larger problem from different angles: can an intervention engage the intended biological system, reach a sufficient effective concentration and change its function? They are areas I am reading and may pursue, not a collection of techniques I expect one laboratory to provide. Strong fundamental research in chemistry, mechanism, materials or instrumentation remains valuable in its own right.

Biological systems that invite better experiments.

These examples come from publications I have read and scientific questions I would like to investigate. I have not experimentally manipulated all these pathways. They are not prerequisites for joining a laboratory: I would welcome equally rigorous work on other receptors, enzymes, biological pathways and disease models.

How questions become testable experiments.

The next two concepts are worked examples of designing a hypothesis and testing it. They demonstrate how I think, not the only projects I would accept. In a chemistry, biomaterials, biology, pharmaceutics, computational or engineering laboratory, I would develop a project around the laboratory’s expertise and a question that can be answered with available methods. PROTAC synthesis, circular-RNA engineering and organ-on-chip construction remain future training goals, not skills I already claim to possess.

A microfluidic organ-on-chip or organoid model could then test a specific tissue barrier or disease state, but its predictive validity must be measured, not presumed. I want to connect molecular chemistry, engineering and quantitative pharmacology through experiments that could ultimately support translation from bench to bedside.

Ideas I learn from across fields.

These selected publications illustrate scientific approaches I admire, not a list of laboratories I will apply to, required future supervisors or research programmes I insist on copying. I read across disciplines because their methods illuminate the problems in my own experimental work.

A researcher in development, not a fixed specialty.

What I bring now: documented experimental chemistry and materials research, cell-based physiological experiments, microscopy and imaging-system implementation, formulation development, quantitative interpretation, scientific writing and collaborative computational research. Each project has its own author-contribution boundaries; the record and source papers document those differences.

Where I could grow: through sustained work on a clearly defined question connecting therapeutic design to exposure or cellular function. Depending on the host laboratory, that may involve medicinal chemistry, chemical biology, pharmacology, drug formulation and PK/PD, polymer and biomaterial engineering, or advanced cell and tissue models. Aptamers, siRNA, circular RNA, PROTACs and targeted conjugates are possible modalities, not fixed requirements. I do not expect one PhD to teach or deploy all of these technologies.

I value careful experimental reasoning regardless of whether the immediate output is a new molecule, an instrument, a biomaterial, a biological mechanism, a dosage form or a therapeutic candidate. For translational projects, I am particularly interested in connecting chemical design to exposure and functional response. For fundamental projects, a strong mechanistic result is worthwhile in its own right.

Research agenda ↑ · Academic profile ↗ · Contact about research ↗